Sanctuary Advisors LLC Grows Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Sanctuary Advisors LLC boosted its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 9.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,727 shares of the biopharmaceutical company’s stock after acquiring an additional 1,484 shares during the quarter. Sanctuary Advisors LLC’s holdings in Dynavax Technologies were worth $197,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in DVAX. Millennium Management LLC purchased a new position in Dynavax Technologies during the second quarter valued at approximately $17,615,000. Great Point Partners LLC grew its stake in shares of Dynavax Technologies by 87.7% during the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock worth $26,660,000 after acquiring an additional 1,109,080 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of Dynavax Technologies in the third quarter worth $8,291,000. PDT Partners LLC acquired a new stake in Dynavax Technologies during the 3rd quarter worth about $3,967,000. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Dynavax Technologies during the 2nd quarter worth approximately $3,144,000. 96.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $29.00 price objective on shares of Dynavax Technologies in a research note on Friday, November 8th.

Dynavax Technologies Stock Down 0.2 %

DVAX stock opened at $13.00 on Monday. The firm’s 50 day moving average price is $12.45 and its 200-day moving average price is $11.54. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The firm has a market cap of $1.71 billion, a PE ratio of 100.01 and a beta of 1.33. Dynavax Technologies Co. has a one year low of $9.74 and a one year high of $15.01.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.